About galmed pharmaceuticals - GLMD
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
GLMD At a Glance
Galmed Pharmaceuticals Ltd.
16 Abba Hillel Road
Ramat Gan, Tel Aviv 5250608
| Phone | 972-3-693-8448 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -10,309,000.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GLMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.313 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.768 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
GLMD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,718,166.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GLMD Liquidity
| Current Ratio | 6.547 |
| Quick Ratio | 6.547 |
| Cash Ratio | 6.425 |
GLMD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -55.534 |
| Return on Equity | -64.213 |
| Return on Total Capital | -65.321 |
| Return on Invested Capital | -64.213 |
GLMD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |